Uniqsis Reports on Expansion
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Uniqsis (Shepreth, UK), a market leader in flow chemistry, reports following excellent business growth in 2017 that it has recruited a further sales / support specialist to be located at its office in Cambridge.
Paul Pergande, Managing Director of Uniqsis commented "We are very pleased to welcome Steve Evans to Uniqsis. Steve's strong technical background as well as his in-depth knowledge of continuous flow reactor equipment and applications will be a major asset to both Uniqsis and its customers worldwide".
Steve Evans said “I am delighted to have joined Uniqsis and am very much looking forward to contributing to the continued success and growth of the company as we move into the next phase of its development”.
During 2017, Uniqsis achieved double-digit growth in North America and Europe with a notable increase in sales of its high performance FlowSyn integrated continuous flow reactor systems for pharmaceutical, nanomaterials and academic research applications.
Reflecting upon technical developments in 2017, Dr Mark Ladlow (Chief Scientific Officer) commented “Our ability to develop unique new products such as our entry-level Flowlab range of modular flow reactor systems, Flow-UV™ in-line UV-Vis detector and offer custom FlowSyn systems has enabled us to provide optimised application solutions for end users in a growing number of end user markets. He added “Investment made possible by our success last year will enable Uniqsis to bring several further new products to market in 2018”.
Paul Pergande, Managing Director of Uniqsis commented "We are very pleased to welcome Steve Evans to Uniqsis. Steve's strong technical background as well as his in-depth knowledge of continuous flow reactor equipment and applications will be a major asset to both Uniqsis and its customers worldwide".
Steve Evans said “I am delighted to have joined Uniqsis and am very much looking forward to contributing to the continued success and growth of the company as we move into the next phase of its development”.
During 2017, Uniqsis achieved double-digit growth in North America and Europe with a notable increase in sales of its high performance FlowSyn integrated continuous flow reactor systems for pharmaceutical, nanomaterials and academic research applications.
Reflecting upon technical developments in 2017, Dr Mark Ladlow (Chief Scientific Officer) commented “Our ability to develop unique new products such as our entry-level Flowlab range of modular flow reactor systems, Flow-UV™ in-line UV-Vis detector and offer custom FlowSyn systems has enabled us to provide optimised application solutions for end users in a growing number of end user markets. He added “Investment made possible by our success last year will enable Uniqsis to bring several further new products to market in 2018”.
